KAS
ABUS icon

Kestra Advisory Services’s Arbutus Biopharma ABUS Stock Holding History

Kestra Advisory Services’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,000
Closed -$43.3K – 2894
2025
Q2 		$43.3K Sell
14,000
-48
-0.3% -$159 ﹤0.01% 2780
2025
Q1 		$49K Buy
+14,048
New +$46.8K ﹤0.01% 2649
2024
Q3 		– Sell
-10,800
Closed -$33.4K – 2549
2024
Q2 		$33.4K Sell
10,800
-223
-2% -$669 ﹤0.01% 2572
2024
Q1 		$28.4K Buy
+11,023
New +$28.6K ﹤0.01% 2422

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kestra Advisory Services's ABUS Position: Q3 2025 in Review

Kestra Advisory Services sold out of Arbutus Biopharma (ABUS) in Q3 2025, closing a stake of 14,000 shares — an estimated $43.3K sold.

Kestra Advisory Services first reported a position in ABUS in Q1 2024 and held it in 4 quarters. The position peaked at $49K in Q1 2025. 166 funds tracked by Wall St. Rank hold ABUS as of Q3 2025.

  • Kestra Advisory Services reported no remaining Arbutus Biopharma position as of Q3 2025 after selling out during the quarter.
  • Kestra Advisory Services sold 14,000 Arbutus Biopharma shares in Q3 2025, an estimated $43.3K.
  • Kestra Advisory Services first reported a position in Arbutus Biopharma in Q1 2024 and held it in 4 quarters.
  • Kestra Advisory Services's Arbutus Biopharma position peaked at $49K in Q1 2025.
  • 166 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2025.

Based on Kestra Advisory Services's 13F filing for Q3 2025, filed 14 Nov 2025.